Back to stock analysis

Scenario-based stock forecast

Research updated: Jul 12, 2026, 12:00 AM UTC

Novo Nordisk A/S (NVO) Stock Forecast & Outlook

This outlook frames possible paths for Novo Nordisk A/S; it is not a guaranteed price target or personalized investment advice.

Novo Nordisk A/S operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Base-case outlook

Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. The base case remains conditional on glp-1 competition staying manageable.

Bull-case outlook

Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. Fill-finish and active-ingredient investments can improve supply and support broader launches. Oral and combination therapies can extend leadership across obesity, diabetes and related conditions.

Bear-case outlook

Rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity. Payer restrictions, government negotiation and affordability concerns can reduce realized economics. Quality findings or delays in complex capacity projects could constrain supply during rapid demand growth.

What could invalidate the outlook

  • Reassess the thesis if rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity.

Evidence and research sources

Financial results for the first three months of 2026Novo Nordisk A/S · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/6/2026, 12:00:00 AM

Open original source
Novo Nordisk A/S Investor RelationsNovo Nordisk A/S · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Novo Nordisk SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/6/2026, 12:00:00 AM

Open original source
Open earnings analysisOpen stock risks